C.A.L.R. (Center for accelerating Leukemia/Lymphoma Research) at Humanitas University

Molecular Biologist

Job Description

One pre-doctoral position is available at CALR (https://www.humanitas.eu/calr/), Humanitas University to study the development and progression of myeloid neoplasms (myelodysplastic syndromes, myeloproliferative neoplasms and acute myeloid leukemia) through multi-omics approaches.

We are looking for a curious, motivated and passionate junior scientist with experience in molecular biology techniques. The ideal candidate would have a degree in Biotechnology, Biological sciences, Genetics or related disciplines and preferably 1-2 years laboratory training in molecular biology. Good English is required.

Responsibilities

The successful candidate will be responsible for preparing samples for Next Generation Sequencing (NGS) experiments, including extraction, quantification, and quality assessment of nucleic acids from bone marrow or peripheral blood. He/She will also be responsible for preparing sequencing libraries for bulk RNA and single-cell sequencing experiments.

Requirements

- Excellent team-working capabilities even with colleagues from different research areas and backgrounds;
- Good communication skills and ability to explain complex technical content to non-technical stakeholders;
- Curiosity and ability of stepping outside your comfort zone.
- Strong self-motivation, commitment and proactive approach;
- Ability to meet deadlines and work autonomously in rapidly changing environments;

- Curiosity and ability of stepping outside your comfort zone.

The candidate will join a growing and stimulating research environment at the interface between the clinics and the lab, in a research institute of excellence.

To apply, please send your CV and a cover letter highlighting your relevant experience to Prof Matteo G Della Porta: matteo.della_porta@hunimed.eu

Selected References

- D'Amico S et al. Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology. J Clin Oncol CCI 2023, in press
- Sauta E et al. Real-world validation of Molecular International Prognostic Scoring System (IPSS-M) for myelodysplastic syndromes. J Clin Oncol 2023 Mar 17;JCO2201784. doi: 10.1200/JCO.22.01784.
- Maggioni G et al. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. Lancet Haematol. 2022 Nov 24:S2352-3026
- Bernard, E et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid 2022; 1 (7); DOI:https://doi.org/10.1056/EVIDoa220000
- Bernard E, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549-1556.
- Bersanelli M, et al. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. J Clin Oncol. 2021 Apr 10;39(11):1223-123
- Rossi M, Clinical relevance of clonal hematopoiesis in persons aged ≥80 years. Blood. 2021 Nov 25;138(21):2093-2105.